Gelonghui September 16th | Several large pharmaceutical companies have already bet on cancer targeted radiotherapy technology - a therapy that delivers radioactive drugs directly to tumors - which will become the next major breakthrough in cancer treatment. Bristol-Myers Squibb, AstraZeneca, Eli Lilly and other pharmaceutical companies have spent about $10 billion on acquisitions or transactions with radioactive drug manufacturers. They have snapped up smaller players in the industry to gain access to technologies that can treat multiple types of cancer. According to Guggenheim Securities analyst Michael Schmidt, "Any large company that has a presence in the field of oncology or considers cancer treatment as an important therapeutic category may need to invest in this area in some way." Novartis has already launched two radioactive drugs. According to Schmidt's statistics, there are dozens of other similar drugs in development. However, he said it is difficult to estimate the total market opportunity for these drugs because they can treat many potential cancers. Schmidt predicts that if this technology is limited to treating only a few types of cancer, such as prostate and neuroendocrine tumors, the revenues in this category could increase to at least $5 billion, and if it proves effective for more cancers, the total revenue could increase to billions of dollars.